Skip to main content
. 2024 Aug 29;20(1):2395680. doi: 10.1080/21645515.2024.2395680

Figure 3.

Figure 3.

Long-term follow up of patients with nmCRPC (NCT00849121). Patients were followed for 5 y for significant medical events. Shown are the times at which patients developed documented metastatic disease (■), started ARSI treatment (brown), or started docetaxel (blue). Time of death due to prostate cancer (●) or other cause (▲) is also shown. Subjects are ordered with respect to the pre-treatment PSA doubling time.